Long-Term Follow-Up of Subjects Treated With NTLA-2002

Status

Recruiting

Phases

Phase 1Phase 2

Study type

Interventional

Source

EU CTIS

Registry ID

CTIS2023-507956-56-00

Acronym

ITL-2002-CL-999

Enrollment

Registered

2023-11-03

Start date

2024-05-17

Completion date

Unknown

Last updated

2025-12-09

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Hereditary Angioedema

Brief summary

Incidence of treatment-related AEs;, incidence of treatment-related SAEs, incidence of treatment-related AESIs defined per protocol

Detailed description

- Rate of HAE attacks overall and rate of HAE attacks requiring acute therapy, - Total plasma kallikrein protein level, - Change from baseline in consumption of on demand HAE medications for attacks, - Change from baseline in healthcare utilization for HAE attacks, - Change from baseline in QoL parameters as measured by the MOXIE Angioedema QoL instrument, EQ-5D-5L, and WPAI:GH

Interventions

DRUGNTLA-2002

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Design outcomes

Primary

Measure	Time frame
Incidence of treatment-related AEs;, incidence of treatment-related SAEs, incidence of treatment-related AESIs defined per protocol	—

Secondary

Measure	Time frame
- Rate of HAE attacks overall and rate of HAE attacks requiring acute therapy, - Total plasma kallikrein protein level, - Change from baseline in consumption of on demand HAE medications for attacks, - Change from baseline in healthcare utilization for HAE attacks, - Change from baseline in QoL parameters as measured by the MOXIE Angioedema QoL instrument, EQ-5D-5L, and WPAI:GH	—

Countries

France, Germany, Netherlands

Outcome results

None listed

Source: EU CTIS · Data processed: Feb 4, 2026